WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > BBVA Research
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy
Biocytogen | June 23, 2021
Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...
Industrial Impact
Leap Therapeutics, Inc. | February 01, 2022
Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...
Medical
Molsentech | July 29, 2022
With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...
Mekonos | November 24, 2020
Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...
MedTech, Medical
Video
Cell and Gene Therapy, Industrial Impact
Whitepaper
Medical, Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE